Bangladesh · Delayed Price · Currency is BDT Advent Pharma Statistics
Total Valuation
Advent Pharma has a market cap or net worth of BDT 1.31 billion. The enterprise value is 1.39 billion.
| Market Cap | 1.31B |
| Enterprise Value | 1.39B |
Important Dates
The last earnings date was Thursday, January 29, 2026.
| Earnings Date | Jan 29, 2026 |
| Ex-Dividend Date | Nov 23, 2025 |
Share Statistics
Advent Pharma has 93.13 million shares outstanding. The number of shares has decreased by -0.63% in one year.
| Current Share Class | 93.13M |
| Shares Outstanding | 93.13M |
| Shares Change (YoY) | -0.63% |
| Shares Change (QoQ) | -4.62% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 22.80.
| PE Ratio | 22.80 |
| Forward PE | n/a |
| PS Ratio | 2.54 |
| PB Ratio | 0.85 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | 150.40 |
| P/OCF Ratio | 19.24 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.56, with an EV/FCF ratio of 158.69.
| EV / Earnings | 24.21 |
| EV / Sales | 2.68 |
| EV / EBITDA | 9.56 |
| EV / EBIT | 16.69 |
| EV / FCF | 158.69 |
Financial Position
The company has a current ratio of 1.70, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.70 |
| Quick Ratio | 1.22 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.52 |
| Debt / FCF | 8.68 |
| Interest Coverage | 9.21 |
Financial Efficiency
Return on equity (ROE) is 3.76% and return on invested capital (ROIC) is 3.97%.
| Return on Equity (ROE) | 3.76% |
| Return on Assets (ROA) | 2.69% |
| Return on Invested Capital (ROIC) | 3.97% |
| Return on Capital Employed (ROCE) | 4.69% |
| Weighted Average Cost of Capital (WACC) | 6.60% |
| Revenue Per Employee | 1.63M |
| Profits Per Employee | 180,544 |
| Employee Count | 317 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 5.41 |
Taxes
In the past 12 months, Advent Pharma has paid 16.62 million in taxes.
| Income Tax | 16.62M |
| Effective Tax Rate | 22.50% |
Stock Price Statistics
The stock price has decreased by -10.76% in the last 52 weeks. The beta is 0.40, so Advent Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -10.76% |
| 50-Day Moving Average | 13.47 |
| 200-Day Moving Average | 14.30 |
| Relative Strength Index (RSI) | 61.90 |
| Average Volume (20 Days) | 196,361 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Advent Pharma had revenue of BDT 516.48 million and earned 57.23 million in profits. Earnings per share was 0.62.
| Revenue | 516.48M |
| Gross Profit | 161.20M |
| Operating Income | 83.00M |
| Pretax Income | 73.85M |
| Net Income | 57.23M |
| EBITDA | 144.34M |
| EBIT | 83.00M |
| Earnings Per Share (EPS) | 0.62 |
Balance Sheet
The company has 3.45 million in cash and 75.79 million in debt, with a net cash position of -72.35 million or -0.78 per share.
| Cash & Cash Equivalents | 3.45M |
| Total Debt | 75.79M |
| Net Cash | -72.35M |
| Net Cash Per Share | -0.78 |
| Equity (Book Value) | 1.55B |
| Book Value Per Share | 16.64 |
| Working Capital | 138.28M |
Cash Flow
In the last 12 months, operating cash flow was 68.26 million and capital expenditures -59.53 million, giving a free cash flow of 8.73 million.
| Operating Cash Flow | 68.26M |
| Capital Expenditures | -59.53M |
| Free Cash Flow | 8.73M |
| FCF Per Share | 0.09 |
Margins
Gross margin is 31.21%, with operating and profit margins of 16.07% and 11.08%.
| Gross Margin | 31.21% |
| Operating Margin | 16.07% |
| Pretax Margin | 14.30% |
| Profit Margin | 11.08% |
| EBITDA Margin | 27.95% |
| EBIT Margin | 16.07% |
| FCF Margin | 1.69% |
Dividends & Yields
This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 0.35%.
| Dividend Per Share | 0.05 |
| Dividend Yield | 0.35% |
| Dividend Growth (YoY) | -50.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 7.57% |
| Buyback Yield | 0.63% |
| Shareholder Yield | 0.98% |
| Earnings Yield | 4.36% |
| FCF Yield | 0.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 28, 2022. It was a forward split with a ratio of 1.02.
| Last Split Date | Feb 28, 2022 |
| Split Type | Forward |
| Split Ratio | 1.02 |
Scores
Advent Pharma has an Altman Z-Score of 2.93 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.93 |
| Piotroski F-Score | 5 |